China regulators offer VIP treatment for 48 overseas drugs they're ready to hustle up with accelerated reviews
China wants novel drugs already approved overseas to be available in the country faster. And in case some drugmakers didn’t get the memo, it’s now come up with a direct appeal.
Eight months after the Chinese drug administration rolled out its new priority review pathway, its Center for Drug Evaluation has unveiled a list of 48 drugs (which you can see below) approved in the US, EU or Japan that are urgently needed in the clinical setting. As long as the companies can provide evidence that the drug works equally well across races, they can immediately apply for marketing approval with the data they have and will be eligible for priority review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.